NasdaqCM:BMRA

Stock Analysis Report

Executive Summary

Biomerica, Inc., together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions.

Snowflake

Fundamentals

High growth potential with adequate balance sheet.

Risks

  • Biomerica is covered by less than 3 analysts.

Similar Companies

Share Price & News

How has Biomerica's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-10.9%

NasdaqCM:BMRA

-1.6%

US Medical Equipment

-1.6%

US Market


1 Year Return

-24.0%

NasdaqCM:BMRA

10.2%

US Medical Equipment

-3.0%

US Market

BMRA underperformed the Medical Equipment industry which returned 10.2% over the past year.

BMRA underperformed the Market in United States of America which returned -3% over the past year.


Share holder returns

BMRAIndustryMarket
7 Day-10.9%-1.6%-1.6%
30 Day-6.9%-3.5%-5.8%
90 Day17.3%7.4%0.2%
1 Year-24.0%-24.0%11.1%10.2%-0.8%-3.0%
3 Year-10.7%-10.7%65.1%60.0%38.0%29.1%
5 Year213.2%213.2%127.0%101.0%50.8%34.1%

Price Volatility Vs. Market

How volatile is Biomerica's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Biomerica undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Biomerica's share price is below the future cash flow value, and at a moderate discount (> 20%).

Biomerica's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Biomerica is loss making, we can't compare its value to the US Medical Equipment industry average.

Biomerica is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Biomerica, we can't assess if its growth is good value.


Price Based on Value of Assets

Biomerica is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Biomerica expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

62.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Biomerica's revenue is expected to grow significantly at over 20% yearly.

Biomerica's earnings are expected to grow significantly at over 20% yearly.

Biomerica's revenue growth is expected to exceed the United States of America market average.

Biomerica's earnings growth is expected to exceed the United States of America market average.

Biomerica's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Biomerica will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Biomerica performed over the past 5 years?

-39.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Biomerica does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Biomerica's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Biomerica's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Biomerica has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Biomerica has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Biomerica improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Biomerica's financial position?


Financial Position Analysis

Biomerica is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Biomerica has no long term commitments.


Debt to Equity History and Analysis

Biomerica has no debt.

Biomerica has not taken on any debt in the past 5 years.


Balance Sheet

High level of physical assets or inventory.

Biomerica has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Biomerica has less than a year of cash runway based on current free cash flow.

Biomerica has less than a year of cash runway if free cash flow continues to grow at historical rates of 66.5% each year.


Next Steps

Dividend

What is Biomerica's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Biomerica's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Biomerica's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Biomerica has not reported any payouts.

Unable to verify if Biomerica's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Biomerica has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Biomerica's salary, the management and board of directors tenure and is there insider trading?

16.1yrs

Average board tenure


CEO

Zackary Irani (53yo)

22.3yrs

Tenure

US$295,081

Compensation

Mr. Zackary S. Irani has been Chairman of the Board and Chief Executive Officer of Biomerica Inc. since April 29, 1997 and served as its President. Mr. Irani serves as the President and Chairman of ReadySc ...


CEO Compensation Analysis

Zackary's remuneration is lower than average for companies of similar size in United States of America.

Zackary's compensation has increased whilst company is loss making.


Board Age and Tenure

16.1yrs

Average Tenure

65yo

Average Age

The average tenure for the Biomerica board of directors is over 10 years, this suggests they are a seasoned and experienced board.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Janet Moore (68yo)

    CFO, Treasurer

    • Tenure: 22.3yrs
    • Compensation: US$166.43k
  • Zackary Irani (53yo)

    Chairman & CEO

    • Tenure: 22.3yrs
    • Compensation: US$295.08k

Board Members

  • Ned Barnholt (75yo)

    Chairman of Strategic Advisory Board

    • Tenure: 0.0yrs
  • Janet Moore (68yo)

    CFO, Treasurer

    • Tenure: 22.3yrs
    • Compensation: US$166.43k
  • Zackary Irani (53yo)

    Chairman & CEO

    • Tenure: 22.3yrs
    • Compensation: US$295.08k
  • Francis Cano (72yo)

    Director

    • Tenure: 20.2yrs
    • Compensation: US$50.29k
  • Mark Sirgo (65yo)

    Director

    • Tenure: 3.1yrs
    • Compensation: US$50.29k
  • Allen Barbieri (61yo)

    Director

    • Tenure: 19.8yrs
    • Compensation: US$50.29k
  • Harry Leider

    Member of Strategic Advisory Board

    • Tenure: 1.3yrs
  • Jane Emerson (65yo)

    Director

    • Tenure: 12.3yrs
    • Compensation: US$60.29k
  • Tony Lembo

    Member of Scientific Advisory Board

    • Tenure: 3.1yrs

Company Information

Biomerica, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Biomerica, Inc.
  • Ticker: BMRA
  • Exchange: NasdaqCM
  • Founded: 1971
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$27.551m
  • Shares outstanding: 9.67m
  • Website: https://www.biomerica.com

Number of Employees


Location

  • Biomerica, Inc.
  • 17571 Von Karman Avenue
  • Irvine
  • California
  • 92614
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BMRANasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJan 1975

Biography

Biomerica, Inc., together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The compa ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/24 23:32
End of Day Share Price2019/08/23 00:00
Earnings2019/02/28
Annual Earnings2018/05/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.